Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01172470 · ClinicalTrials.gov registry record · Phase 2

Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients

A Phase 2 study, sponsored by University of Chicago.

Completed
Registry status
Phase 2
Development phase
34
Enrollment target

NCT01172470: Completed Phase 2 study, sponsored by University of Chicago.

NCT01172470 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01172470, a Phase 2 study, has completed, sponsored by University of Chicago.

COMPLETED
Registry status
Phase 2
Development phase
34 participants
Enrollment target

Study Summary

The purpose of this study is to determine 1-year survival of previously irradiated Head and Neck cancer (HNC) patients with loco-regional recurrent disease treated with induction chemotherapy with pemetrexed and gemcitabine followed concomitant pemetrexed, carboplatin and daily radiotherapy.

Interventions

  • DRUG Carboplatin
  • DRUG Pemetrexed
  • DRUG Gemcitabine

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2005-06
Est. Completion 2010-07
Phase Phase 2
University of Chicago

796 total trials

What the finished NCT01172470 record still lists

NCT01172470 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).

The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.

NCT01172470 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01172470 about?

NCT01172470 is a clinical study titled "Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients". The purpose of this study is to determine 1-year survival of previously irradiated Head and Neck cancer (HNC) patients with loco-regional recurrent disease treated with induction chemotherapy with pemetrexed and gemcitabine followed concomitant pemetrexed, carboplatin and daily radiotherapy.

What is the current status of trial NCT01172470?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2005-06. Estimated completion is 2010-07.

What interventions are being tested in trial NCT01172470?

The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Gemcitabine (DRUG).

Who is sponsoring clinical trial NCT01172470?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01172470's enrollment target sits among peer trials

34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01172470, the US trial registry maintained by the National Library of Medicine. NCT01172470 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.